SVA

Sinovac Biotech
SVA

 

About: Sinovac Biotech Ltd is a China-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including, without limitation, hepatitis A, hepatitis B, hand foot and mouth disease (HFMD) caused by EV71, seasonal influenza, H5N1 and H1N1 pandemic influenza, coronavirus, pneumococcus, poliomyelitis, varicella and mumps.

Employees: 3,261

0
Funds holding %
of 6,702 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

1,900% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 0

238% more funds holding

Funds holding: 8 [Q4 2023] → 27 (+19) [Q1 2024]

50% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2023] → 3 (+1) [Q1 2024]

22% more capital invested

Capital invested by funds: $345M [Q4 2023] → $421M (+$75.5M) [Q1 2024]

19.42% more ownership

Funds ownership: 4.51% [Q4 2023] → 23.93% (+19.42%) [Q1 2024]

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Research analyst outlook

We haven’t received any recent analyst ratings for SVA.

Financial journalist opinion